Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease ; volume:20 ; number:1 ; day:23 ; month:10 ; year:2021 ; pages:1-11 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (23.10.2021), 1-11, 12.2021
- Creator
-
Shao, Shih-Chieh
Chang, Kai-Cheng
Lin, Swu-Jane
Chang, Shang-Hung
Hung, Ming-Jui
Chan, Yuk-Ying
Lai, Edward Chia-Cheng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-021-01406-3
- URN
-
urn:nbn:de:101:1-2022010319510630260002
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shao, Shih-Chieh
- Chang, Kai-Cheng
- Lin, Swu-Jane
- Chang, Shang-Hung
- Hung, Ming-Jui
- Chan, Yuk-Ying
- Lai, Edward Chia-Cheng
- SpringerLink (Online service)
Other Objects (12)
SGLT2 inhibitors in heart failure with reduced ejection fraction
Sex disparities in outcomes among hospitalizations for heart failure
SGLT2 and cancer
Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score
Recurrent Hospitalizations for Fluid Overload in Diabetes with Kidney Failure Treated with Dialysis
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Quality reporting of randomized controlled trials on SGLT2 inhibitors for heart failure: a comprehensive assessment
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
The effect and burden modification of heating on adult asthma hospitalizations in Shijiazhuang: a time-series analysis
SGLT2 inhibitors in heart failure with reduced ejection fraction
Sex disparities in outcomes among hospitalizations for heart failure
SGLT2 and cancer
Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score
Recurrent Hospitalizations for Fluid Overload in Diabetes with Kidney Failure Treated with Dialysis
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Quality reporting of randomized controlled trials on SGLT2 inhibitors for heart failure: a comprehensive assessment
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection
The effect and burden modification of heating on adult asthma hospitalizations in Shijiazhuang: a time-series analysis
SGLT2 inhibitors in heart failure with reduced ejection fraction
Sex disparities in outcomes among hospitalizations for heart failure
SGLT2 and cancer
Prediction of recurrent heart failure hospitalizations and mortality using the echocardiographic Killip score
Recurrent Hospitalizations for Fluid Overload in Diabetes with Kidney Failure Treated with Dialysis
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
Quality reporting of randomized controlled trials on SGLT2 inhibitors for heart failure: a comprehensive assessment
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal Protection